GlassScriptPhysician profile
Patrick J Polsunas
NPI 1366972549
$2,289.65
in general payments reported to CMS, 2019-2025
13 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $412 · 2022: $1,088 · 2023: $443 · 2024: $90.19 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stimwave Technologies Incorporated | $669.51 | 2022 | |
| Boston Scientific Corporation | $468.76 | 2022-2025 | Wavewriter Alpha Prime 16, Intracept |
| Medtronic, INC. | $411.87 | 2021 | |
| Nalu Medical, INC. | $216.10 | 2023-2025 | Nalu Neurostimulation System |
| Abbott Laboratories | $198.98 | 2022-2025 | Eterna, Proclaim |
| Si-Bone, INC. | $58.29 | 2024-2025 | |
| Mml US, INC. | $57.84 | 2025 | Reactiv8 |
| Vertex Pharmaceuticals Incorporated | $52.70 | 2024 | |
| Curonix LLC | $51.91 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $38.89 | 2023 | |
| Spr Therapeutics, INC | $26.30 | 2025 | Sprint Pns System |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.50 | 2023 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Polsunas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.